Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ß-thalassemia. The FULC average annual return since 2019 is shown above.
The Average Annual Return on the FULC average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FULC average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FULC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|